Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
WAYNE, Pa., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Clinical Trial
Ceapro Inc. Reports Record 2022 Second Quarter and Six-Month Financial Results and Provides Corporate Update
– Company boasts highest second quarter sales to date; Q2 2022 sales of $5,500,000 vs $4,409,000 in Q2 2021, a...
Aviv Clinics and Sagol Center for Hyperbaric Medicine and Research Present Webinar on Research Findings from the First Long COVID Clinical Trial to Show Symptom Relief
August 29 webinar will detail the research and success of the clinical trial from the Sagol CenterORLANDO, Fla., Aug. 24,...
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three...
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need - NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences...
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
IRVINE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to...
Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors
Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from...
Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial
Sepsis Phase II protocol amendments have been cleared by regulatory authorities in Israel, Spain, and Greece. In addition to these...
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent...
Ayala Pharmaceuticals Selected to Present Efficacy and Tolerability Data on AL102 in Desmoid Tumors at the European Society for Medical Oncology (ESMO) 2022 Congress
Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical studyREHOVOT, Israel and WILMINGTON, Del., Aug....
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal...
New Science Technology Accelerates Patient Recruitment and Enrollment
Patient relationship management and contact center technology enables Science 37 to achieve significantly greater patient engagementRESEARCH TRIANGLE PARK, N.C., Aug....
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022...
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022
Presentation will highlight opportunity for oral difelikefalin to address a significant unmet need in the treatment of pruritus in patients...
Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer
COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company...
Bavarian Nordic Announces First Half 2022 Results
COPENHAGEN, Denmark, August 24, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress...
Sorrento Announces Significant Positive Pivotal Trial Results as Assessed by an Independent Review Committee (IRC) With Matured Long-Term (Over Three Years) Follow-Up Data of Abivertinib for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Abivertinib is a novel third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced...
Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy
Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure SION™ Surgical Instrument by Sight Sciences, Inc....
Recce Pharmaceuticals Announces Positive Safety Data from Seventh Cohort of Phase 1 Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: 10 subjects in cohort seven were intravenously dosed with RECCE® 327 at 6,000mg Independent Safety Committee reviewing cohort seven...
Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers
Initial focus of five-year collaboration will be on potentially best-in-class ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, which together comprise...